Formulation of biologics for alternative routes of administration: Current problems and perspectives

Introduction: Biologics (biopharmaceuticals) present new promising therapies for many diseases such as cancers, chronical inflammatory and today's biggest challenge - COVID-19. Research: Today, most biologics have been synthetized using modern methods of biotechnology, in particular DNA recombinant technology. Current pharmaceutical forms protein/peptide biopharmaceuticals are intended parenteral route administration due to their instability large size molecules. In order improve patient compliance, companies working on developing adequate alternative, non-invasive routes administration. The aim this work is review current aspirations problems formulation alternative (non-parenteral) the attempts overcome them. These could be prevention treatment COVID-19, among other serious diseases. Conclusion: emphasis stabilizing monoclonal antibodies into special formulations delivery systems; application should safer, more comfortable reliable. When it comes hormones, vaccines smaller peptides, some already registered drugs nasal oral delivery.